Celgene Co. The company has a market cap of $71,650.00, a P/E ratio of 18.14, a price-to-earnings-growth ratio of 0.67 and a beta of 1.49. (CELG) traded down $0.88 during trading hours on Friday, hitting $95.26. Insiders have sold a total of 38,733 shares of company stock worth $5,259,359 in the last three months.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, January 25th. It has outperformed by 0.30% the S&P500.
Awm Investment Company Inc increased its stake in Digimarc Corporation (DMRC) by 24.43% based on its latest 2017Q3 regulatory filing with the SEC. Lombard Odier Asset Management Usa Corp sold 30,000 shares as the company's stock rose 5.22% with the market. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company's stock valued at $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Lombard Odier Asset Management Usa Corp who had been investing in Nxp Semiconductors N V for a number of months, seems to be less bullish one the $40.18B market cap company. About 5.21 million shares traded or 1.09% up from the average. (UCBI) has risen 34.83% since February 17, 2017 and is uptrending. It has underperformed by 0.05% the S&P500.
In other news, insider Mark J. Alles purchased 3,260 shares of the company's stock in a transaction dated Thursday, February 8th. On Monday, October 2 Moriarty Thomas M sold $1.67 million worth of CVS Health Corporation (NYSE:CVS) or 20,547 shares. Following the transaction, the director now owns 9,250 shares of the company's stock, valued at approximately $1,286,027.50. $7.13M worth of stock was sold by Roberts Jonathan C on Monday, September 18.
Horan Capital Management, which manages about $446.88 million and $481.22 million US Long portfolio, decreased its stake in General Electric Co (NYSE:GE) by 13,398 shares to 511,500 shares, valued at $12.37 million in 2017Q3, according to the filing. Its down 0.04, from 0.92 in 2017Q2. Greenleaf Tru invested in 90,893 shares. 93 funds opened positions while 240 raised stakes. Sigma Inv Counselors reported 29,239 shares. Columbia Asset Mngmt owns 5,969 shares for 0.27% of their portfolio. Strs Ohio reported 0.57% stake. Cacti Asset Mngmt Lc owns 576,253 shares. Hilton Capital Mngmt Limited Liability invested in 0.17% or 6,545 shares. Wedgewood Inc Pa reported 2,500 shares. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company's stock valued at $1,635,643,000 after buying an additional 697,250 shares in the last quarter. 92 were accumulated by Thompson Davis Communication. Susquehanna Group Inc Limited Liability Partnership holds 33,713 shares. The Massachusetts-based Wade G W & has invested 0.03% in Activision Blizzard, Inc. Jackson Square Prtnrs Ltd Liability Company owns 4.49% invested in Celgene Corporation (NASDAQ:CELG) for 6.35M shares. Banced stated it has 5,486 shares. Security National Trust Co. lifted its holdings in Celgene by 8.0% during the 2nd quarter. Therefore 83% are positive. Dominion Midstream Partners LP had 33 analyst reports since July 23, 2015 according to SRatingsIntel.
Ryan Mason: 'I could go into coaching'
Mason clashed heads with Cahill in a match at Stamford Bridge early previous year and fractured his skull in the incident. If we were lucky to play on Friday, we were very unlucky to have this schedule.
First Financial Bank - Trust Division, which manages about $590.72M US Long portfolio, decreased its stake in Procter & Gamble Company (NYSE:PG) by 4,855 shares to 302,472 shares, valued at $27.52 million in 2017Q3, according to the filing. The stock of NXP Semiconductors N.V. (NASDAQ:NXPI) has "Buy" rating given on Thursday, October 27 by Mizuho. Cantor Fitzgerald maintained Celgene Corporation (NASDAQ:CELG) rating on Thursday, July 6. Leerink Swann upgraded the stock to "Outperform" rating in Friday, June 16 report. The stock has "Equal-Weight" rating by Barclays Capital on Friday, October 20. The stock has "Accumulate" rating by Johnson Rice on Monday, May 9. $248,498 worth of Celgene Corporation (NASDAQ:CELG) was sold by Curran Terrie.
Investors sentiment decreased to 1.17 in 2017 Q3. The biopharmaceutical company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.78 by $0.09. It fall, as 60 investors sold CVS shares while 571 reduced holdings.
Several other hedge funds and other institutional investors also recently made changes to their positions in CELG. Palisade Management Llc Nj holds 0.01% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 2,010 shares. Meeder Asset Mgmt has 14,089 shares. Valley Advisers Inc invested in 7,787 shares. Gm Advisory Gru holds 0.14% or 3,104 shares in its portfolio. Arrow Financial holds 0% of its portfolio in Digimarc Corporation (NASDAQ:DMRC) for 200 shares. Stratos Wealth Prns Limited, Ohio-based fund reported 10,137 shares. Celgene Corp now has $71.65B valuation. State Of New Jersey Common Pension Fund D reported 0.3% in Celgene Corporation (NASDAQ:CELG). The biopharmaceutical company reported $1.87 EPS for the quarter, beating the Zacks' consensus estimate of $1.78 by $0.09. Brown Brothers Harriman And holds 0.01% or 9,196 shares in its portfolio. Ifc Inc Fl has invested 0.19% in Celgene Corporation (NASDAQ:CELG). Renaissance Limited Liability Company reported 0.07% of its portfolio in Celgene Corporation (NASDAQ:CELG). Therefore 58% are positive. Celgene Corporation had 132 analyst reports since July 21, 2015 according to SRatingsIntel. Canaccord Genuity has "Buy" rating and $15600 target. The stock of NXP Semiconductors N.V. (NASDAQ:NXPI) has "Buy" rating given on Friday, October 30 by Canaccord Genuity. Barclays Capital maintained Celgene Corporation (NASDAQ:CELG) rating on Friday, October 20. The firm has "Buy" rating by Needham given on Monday, June 19. As per Friday, November 10, the company rating was maintained by Robert W. Baird. UBS maintained it with "Buy" rating and $145 target in Friday, November 6 report. As per Friday, October 27, the company rating was maintained by Needham. The stock of Celgene Corporation (NASDAQ:CELG) earned "Buy" rating by BTIG Research on Thursday, August 4. The company was maintained on Tuesday, September 26 by Cantor Fitzgerald. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases.
Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.